Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05592132
Other study ID # 2022/CHU/11
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 17, 2023
Est. completion date October 2025

Study information

Verified date September 2023
Source Centre Hospitalier Universitaire de la Réunion
Contact Yves REGUERRE
Phone +262262905676
Email yves.reguerre@chu-reunion.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

DOREVI is a monocentric randomized controlled study that will evaluate the efficacy of virtual reality helmets for pain prevention during invasive care on 78 oncologic pediatric patients. Two groups of children (between 6 and 11 and between 12 and 18 years old) will be randomized to use helmet plus standard care or standard care alone during invasive procedures (central venous catheter puncture, lumbar puncture, or bone marrow aspiration). The pain intensity will be evaluated using a visual analogic scale during three invasive procedures, and results will be compared between the patients with or without virtual reality.


Recruitment information / eligibility

Status Recruiting
Enrollment 74
Est. completion date October 2025
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria: - patient who tolerates the virtual reality headset - patient followed in pediatric oncology - patient with a diagnosis of benign tumor or cancer - patient who needs to have painful medical procedure during their treatment - patient whose parents have signed the informed consent - patient affiliated with social security or equivalent Exclusion Criteria: - patient with visual or hearing impairement - patient with epilepsy or other neurological disease - patient with psychiatric disease

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Virtual reality headset
Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.

Locations

Country Name City State
Réunion CHU de La Réunion Saint-Denis

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de la Réunion

Country where clinical trial is conducted

Réunion, 

Outcome

Type Measure Description Time frame Safety issue
Primary Self pain evaluation Pain will be assessed by the analogic visual scale (minimal score = 0 (no pain) , maximal score = 10 (maximal pain)) before blood sampling on catheter with implantable chamber
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03728543 - the Efficacy and Safety of Sugammadex in Children 0-2 Years Old Phase 2/Phase 3
Recruiting NCT04471961 - Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia N/A
Not yet recruiting NCT04856020 - Role of Gray Scale and Color Doppler Ultrasound in Diagnosis of Pediatric Neck Masses